

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

INSIDE INFORMATION

ESTABLISHMENT OF NEW BIOLOGICS CENTRE IN SHIJIAZHUANG, CHINA

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company plans to build an integrated biologics development, clinical and commercial manufacturing centre in the city of Shijiazhuang, capital of Hebei province in northern China (the “**New Biologics Centre**”). It is intended that the New Biologics Centre will include process development labs, clinical manufacturing facility with 5,000L bioreactor capacity (MFG9) and commercial manufacturing facility with 48,000L bioreactor capacity (MFG8), which will be built to meet the cGMP (Current Good Manufacturing Practice) standards of the United States, the European Union and China. Apart from serving its global clients, the New Biologics Centre will also support the Marketing Authorization Holding (MAH) system in China and address the urgent needs of the Chinese partners of the Group. It is expected that the initial phase of the New Biologics Centre will commence operation in 2020.

Upon completion, the New Biologics Centre will become one of the largest biologics centres in northern China, which will enable local companies to develop and manufacture biologics more effectively and also provide a robust supply chain network for the Group's global clients. The Board believes that it will add substantial capacity to the Group's existing process development labs, clinical and commercial manufacturing facilities and enhance flexibility and efficiency of its services to the China and global customers, which ultimately benefits patients worldwide. The New Biologics Centre will help the Group to expand quickly and become one of the global contract manufacturing organization (CMO) leaders.

The Board is of the view that the proposed construction of the New Biologics Centre, which is intended to be for the Group's own use in the ordinary and usual course of business, is in the interests of the Company as well as its shareholders as a whole. Further announcement(s) will be made by the Company in accordance with the applicable requirements under the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, May 16, 2018

As of the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*